Edith Perez is an internationally renowned translational researcher and cancer specialist. She is known for her strategic vision in designing innovative clinical trials, her passion for patient care, and her strong team leadership. Want to discover how her work intersects with the ? You’ve come to the right place on pioneer-technology.com. This article explores her multifaceted career, focusing on her contributions to oncology, biotechnology, and academic research, while also examining potential collaborations and impacts on scientific advancements in Puerto Rico. This includes translational clinical trials, biomarker research, and precision medicine breakthroughs.
1. What Are Edith Perez’s Key Skills and Abilities in Oncology?
Edith Perez possesses a diverse skill set honed through years of experience in medical leadership, translational clinical trials, and drug development. Her abilities span from early-stage to late-stage drug development, with a focus on oncology.
- Medical leadership for oncology drug development, translational clinical trials, biomarkers, and precision medicine are among her core competencies. Her expertise facilitates the creation and execution of innovative clinical trials.
- She excels in the development and leadership of translational trials designed with global and U.S. regulatory intent. This ensures adherence to stringent standards and paves the way for successful product launches.
- Dr. Perez is experienced in product/trial late and early-stage (first-in human) drug development. This includes her work at Genentech/Roche, Mayo Clinic, and Bolt Biotherapeutics, demonstrating a broad understanding of the drug development lifecycle.
- Her leadership extends to multiple NCI (National Cancer Institute) projects and committees. This highlights her influence in shaping national cancer research agendas.
- She is an excellent communicator, capable of influential interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders. Her communication skills enable her to effectively convey complex scientific information.
- Dr. Perez is media trained, allowing her to represent institutions/companies and their programs to external audiences, including investment, medical, and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators/partners. This skill enhances the visibility and credibility of her work.
- She fosters a corporate culture of ethical & scientific rigor for decision-making. This is essential for maintaining integrity and driving innovation in medical research.
- Dr. Perez is adept at creating innovative and collaborative partnerships, such as with Stand Up to Cancer, MD Anderson Cancer Center, American Association for Cancer Research (AACR), and imCORE (Immunotherapy Centers of Research Excellence). These collaborations amplify the impact of her research.
- She demonstrates open and transparent leadership, with a goal and people-oriented approach. This makes her innovative, collaborative, visionary, inspirational, and accountable.
2. What Is Edith Perez’s Role at Bolt Biotherapeutics, Inc.?
At Bolt Biotherapeutics, Inc., Edith Perez holds the position of Chief Medical Officer, where she oversees the clinical, regulatory, and strategic aspects of the company’s operations.
As Chief Medical Officer since April 2020, she is responsible for the overall leadership, oversight, and management of clinical, regulatory, pharmacovigilance, biostatistics, and medical affairs activities. Her role is pivotal in steering the company’s clinical development programs.
Dr. Perez is responsible for the strategy, direction, fiscal planning, and execution of clinical development plans. This involves aligning clinical strategies with the company’s goals and ensuring efficient resource allocation.
She directs the development of clinical/translational strategies and plans to integrate Bolt’s clinical candidate therapeutics into the standard practice of oncology/hematology malignancies. This includes designing studies to evaluate the efficacy and safety of new therapies.
Dr. Perez provides oversight for clinical aspects of regulatory strategies and interactions with Health Authorities. She ensures that regulatory submissions are comprehensive and compliant with guidelines, facilitating the approval of new therapies.
She leads interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders. This helps build collaborations and gather insights to inform clinical development.
Dr. Perez oversees the analysis and interpretation of clinical trial data and the reporting of clinical trial results. She ensures that data is accurately analyzed and communicated to the scientific community.
She leads the evolution of the clinical organization in terms of vision, culture, and succession, as well as broad effectiveness and reach that is consistent with the Company’s mission. This involves creating a supportive and innovative environment for clinical teams.
3. How Did Edith Perez Contribute to Genentech/Roche?
During her tenure at Genentech/Roche, Edith Perez held significant leadership positions, contributing to the advancement of cancer immunotherapy and the launch of multiple oncology drugs.
From 2015 to 2018, she served as the Head of US BioOncology and Vice President of US Medical Affairs. In these roles, she co-led the Global Cancer Immunotherapy Group and was a member of the Joint Oncology Leadership Team and Medical Leadership Team.
Dr. Perez led a diverse medical portfolio of hematologic & solid tumor malignancies, with strategic and budgetary responsibilities totaling $200M for pre- and post-commercial trials. Her leadership was pivotal in advancing cancer therapies.
She managed a comprehensive clinical and translational portfolio spanning investigational & marketed products, integration of biomarkers, and scientific collaborations with academic institutions and foundations. This comprehensive approach accelerated drug development.
As a member of the Cancer Immunotherapy Governance Committee, she co-led the development of a global cancer immunotherapy group (imCORE), fostering collaboration between early drug development, medical affairs, product development, and academic institutions in multiple countries.
She led, mentored, & managed a complex organizational team of 150 professionals. Her leadership skills fostered a collaborative and productive environment.
Dr. Perez was an executive member of the Foundation of NIH PACT (Program for Accelerating Cancer Therapies) Immune Biomarker project, representing Genentech. This involvement underscored her commitment to biomarker research.
She oversaw the assessment and funding of >300 translational trials with multiple investigators in the U.S. and globally. These trials significantly contributed to the advancement of cancer research.
Dr. Perez provided leadership for the development of 9 phase III registrational trials with regulatory intent in the U.S. These trials were crucial for securing regulatory approvals for new drugs.
She provided oversight for U.S. BioOncology Advisory Boards (hematologic and solid tumors). Her guidance ensured that clinical strategies were aligned with the latest scientific advances.
Dr. Perez led the preparation and successful medical launches in the U.S. oncology market, including:
- Alecensa as second-line and also first-line therapy for patients with ALK+ non-small cell lung cancer
- Perjeta as adjuvant and neoadjuvant therapy for patients with early-stage HER2+ breast cancer
- Tecentriq as second-line and then first-line bladder cancer
- Tecentriq as second-line for refractory non-small cell lung cancer
- Gazyva as first-line therapy for patients with follicular lymphoma
- Venetoclax as second-line therapy for patients with 17p- chronic lymphocytic leukemia
- Rituxan Hycela for the management of multiple hematologic malignancies
These launches significantly expanded treatment options for cancer patients.
4. What Were Edith Perez’s Contributions at Mayo Clinic Cancer Center?
At Mayo Clinic Cancer Center, Edith Perez made substantial contributions as a professor, researcher, and leader, focusing on translational research and clinical trials.
From 1995 to the present, she served as an Assistant Professor, progressing to Professor of Medicine as of 2001, in the Department of Cancer Biology and the Department of Hematology/Oncology. Her academic career has been marked by significant research and leadership roles.
She authored more than 400 peer-reviewed articles, contributing significantly to the scientific literature on cancer research.
Dr. Perez secured multiple NCI and NIH extramurally funded grants, including R01 grants, until 2015. This funding supported her extensive research activities.
She was an active grant recipient (2015-2020) as Co-Principal Investigator for a Department of Defense grant focused on basic research, development, and conducting a randomized phase II trial for a newly developed vaccine for patients with triple-negative breast cancer.
Dr. Perez held multiple committee memberships and leadership positions with ASCO and AACR, contributing to the direction of these influential organizations.
She served in leadership roles in IDMC (Independent Monitoring Boards) with various pharmaceutical companies, addressing targeted and immune therapies, biomarkers, and precision medicine. Companies included Merck, BMS, Amgen, and Novartis.
Dr. Perez participated in Institute of Medicine (IOM) Committees with goals to offer national recommendations to reorganize the NCI-sponsored Cooperative Groups System and the use of biomarkers for use of molecularly targeted therapies.
She was a member of multiple NCI committees, including the Board of Scientific Advisors (BSA) and Clinical Trials and Translational Committee (CTAC).
Dr. Perez served as Group Vice-Chair of the Alliance of Clinical Trials in Oncology (NCI-sponsored cancer cooperative group until 2015).
She was the Deputy Director at Large, Mayo Clinic Cancer Center (2010-2015), contributing to the strategic direction of the center.
5. How Did Edith Perez’s Early Career Shape Her Expertise?
Edith Perez’s early career, spanning medical school in Puerto Rico, training in New York and California, and early academic roles, laid the foundation for her expertise in oncology and translational research.
Her medical degree from the University of Puerto Rico School of Medicine in San Juan provided her with a strong foundation in medicine.
Electives at Mt. Sinai Hospital in NY and residency and fellowship training in California exposed her to diverse medical environments and practices.
Serving as a general internist in the Division of National Health Services Corps, Los Angeles, provided valuable clinical experience.
Her Hematology/Oncology fellowship at the University of California, Davis School of Medicine, honed her expertise in cancer treatment and research.
Dr. Perez pursued additional leadership, management, and executive development at The Wharton School of the University of Pennsylvania and Harvard Kennedy School in Boston. This prepared her for leadership roles in academic and industry settings.
She is board certified in internal medicine, medical oncology, and hematology, underscoring her expertise in these fields.
6. What Notable Clinical Trial Did Edith Perez Lead?
Edith Perez was the principal investigator of the NCI-funded N9831 trial, a pivotal study that demonstrated the impactful data of adding trastuzumab (Herceptin®) to improve disease-free and overall survival for patients with early-stage HER2-positive breast cancer.
This work set a new standard of care for women globally, including leadership in standards for molecular tissue testing. The data from this study were used for regulatory agency approvals globally and provided a platform for educational activities and discussions with a wide range of health care professionals throughout the world.
According to research published in the New England Journal of Medicine in 2005, the addition of trastuzumab to adjuvant chemotherapy significantly improved outcomes for women with HER2-positive breast cancer.
7. How Is Edith Perez Involved in Philanthropic Endeavors?
Edith Perez is actively involved in philanthropic endeavors, particularly through her co-development of the 26.2 National Marathon to Finish Breast Cancer.
She is the co-developer of the 26.2 National Marathon to Finish Breast Cancer (breastcancermarathon.com), with goals to raise funds for underserved women and genomics/immunologic translational cancer research.
More than 10,000 families have received assistance from the proceeds, and more than $4M has been raised for cancer research.
This initiative exemplifies her commitment to advancing research and providing support to those in need.
8. How Does Edith Perez Promote Diversity and Health Equity?
Edith Perez is deeply committed to promoting diversity and health equity through her involvement with ASCO, AACR, and Stand Up to Cancer.
She has been involved in multiple diversity leadership initiatives with ASCO and AACR, advocating for increased representation and inclusion in these organizations.
Currently, she serves as the Chair of the Health Equity Committee for Stand Up to Cancer, leading efforts to address disparities in cancer care and research.
Her work in this area underscores her dedication to ensuring that all individuals have access to quality healthcare and opportunities for scientific advancement.
9. How Does Edith Perez’s Background Connect with Puerto Rico Science Technology & Research Trust?
Dr. Perez’s Puerto Rican heritage and extensive experience in medical research and innovation could significantly benefit the Puerto Rico Science Technology & Research Trust.
Her Puerto Rican roots provide a cultural connection that could foster collaboration and engagement with local scientists and researchers.
Her experience in leading translational clinical trials, developing biomarkers, and implementing precision medicine initiatives could inform and enhance the Trust’s strategic direction.
Her leadership roles in academic, biopharmaceutical, and philanthropic organizations could bring valuable expertise and resources to support the Trust’s mission.
Her focus on health equity and diversity could help the Trust address healthcare disparities and promote inclusive research initiatives in Puerto Rico.
10. How Can Puerto Rico Science Technology & Research Trust Leverage Edith Perez’s Expertise?
The Puerto Rico Science Technology & Research Trust could leverage Edith Perez’s expertise through several strategic initiatives aimed at fostering innovation and advancing scientific research in Puerto Rico.
The Trust could invite Dr. Perez to serve as a strategic advisor, providing insights and guidance on the development of research programs and initiatives. This would help align the Trust’s efforts with global best practices.
The Trust could partner with Dr. Perez to establish collaborative research projects focused on addressing specific healthcare challenges in Puerto Rico, such as cancer disparities. These projects could leverage Dr. Perez’s expertise in translational research and clinical trials.
The Trust could organize workshops and seminars led by Dr. Perez to train local scientists and researchers in cutting-edge research methodologies and technologies. This would enhance the skills and capabilities of the local scientific community.
The Trust could support initiatives that promote diversity and inclusion in STEM fields, drawing on Dr. Perez’s experience in health equity and diversity leadership. This would help create a more inclusive and equitable research environment in Puerto Rico.
The Trust could facilitate connections between Dr. Perez and local biotech companies and startups to foster innovation and entrepreneurship in the life sciences sector. This would help drive economic growth and create new opportunities for Puerto Rican scientists and entrepreneurs.
11. What Are Potential Collaborative Projects Between Edith Perez and Puerto Rico Science Technology & Research Trust?
Several potential collaborative projects could be initiated between Edith Perez and the Puerto Rico Science Technology & Research Trust, leveraging her expertise to advance scientific research and healthcare in Puerto Rico.
A collaborative research project focused on cancer disparities in Puerto Rico could be established, leveraging Dr. Perez’s expertise in oncology and translational research. This project could investigate the underlying causes of these disparities and develop targeted interventions to improve outcomes.
A clinical trial network could be developed in Puerto Rico, building on Dr. Perez’s experience in leading clinical trials at Mayo Clinic and Genentech/Roche. This network could provide access to cutting-edge therapies for patients in Puerto Rico and contribute to the advancement of medical knowledge.
A mentorship program could be created to pair young Puerto Rican scientists and researchers with Dr. Perez and other leading experts in their fields. This program could provide valuable guidance and support to help these individuals advance their careers.
A series of educational workshops and seminars could be organized, featuring Dr. Perez and other experts, to train local healthcare professionals and researchers in the latest advances in cancer treatment and prevention. This would help improve the quality of care for patients in Puerto Rico.
An initiative could be launched to promote STEM education and careers among young people in Puerto Rico, drawing on Dr. Perez’s passion for education and her commitment to diversity and inclusion. This initiative could help build a pipeline of talented scientists and researchers in Puerto Rico.
12. What Is the Significance of Edith Perez’s Work in Precision Medicine?
Edith Perez’s work in precision medicine is highly significant, as it focuses on tailoring medical treatment to the individual characteristics of each patient, particularly in oncology.
Her expertise in biomarkers and molecularly targeted therapies has been instrumental in advancing precision medicine approaches.
Her involvement in Institute of Medicine (IOM) Committees, which focus on the use of biomarkers for molecularly targeted therapies, highlights her commitment to this field.
Her leadership in IDMC (Independent Monitoring Boards) with various pharmaceutical companies addressing targeted and immune therapies demonstrates her practical application of precision medicine principles.
Precision medicine promises to revolutionize cancer treatment by allowing doctors to select the most effective therapies based on a patient’s genetic makeup and other individual factors.
According to a 2015 report by the National Research Council, precision medicine has the potential to transform healthcare by enabling more personalized and effective treatments.
13. How Has Edith Perez Influenced Global Standards in Breast Cancer Treatment?
Edith Perez’s leadership in the N9831 trial, which demonstrated the benefits of adding trastuzumab to treat HER2-positive breast cancer, has set a new standard of care for women globally.
The data from this study were used for regulatory agency approvals worldwide and have informed treatment guidelines and protocols.
Her work has influenced standards for molecular tissue testing, ensuring that patients receive accurate diagnoses and appropriate treatments.
Her educational activities and discussions with healthcare professionals around the world have disseminated knowledge and best practices in breast cancer treatment.
As noted in a 2005 article in the New England Journal of Medicine, the N9831 trial results significantly improved outcomes for women with HER2-positive breast cancer, establishing trastuzumab as a key component of adjuvant therapy.
14. What Role Do Biomarkers Play in Edith Perez’s Research?
Biomarkers play a crucial role in Edith Perez’s research, as they provide valuable insights into disease processes and can help predict how patients will respond to treatment.
Her work involves the integration of biomarkers into clinical trials and the development of new biomarkers for cancer diagnosis and prognosis.
Her involvement in the Foundation of NIH PACT (Program for Accelerating Cancer Therapies) Immune Biomarker project demonstrates her commitment to biomarker research.
Her leadership in IDMC (Independent Monitoring Boards) with various pharmaceutical companies addressing biomarkers underscores the importance of biomarkers in drug development.
Biomarkers can help identify patients who are most likely to benefit from a particular therapy and can also be used to monitor treatment response and detect early signs of recurrence.
According to the National Cancer Institute, biomarkers are essential tools for precision medicine, enabling doctors to tailor treatment to individual patients based on their unique characteristics.
15. What Is Edith Perez’s Perspective on the Future of Cancer Therapy?
Edith Perez envisions a future of cancer therapy that is more personalized, targeted, and effective, driven by advances in precision medicine, immunotherapy, and translational research.
Her work reflects a commitment to developing new therapies that harness the power of the immune system to fight cancer.
Her focus on translational research aims to bridge the gap between basic science discoveries and clinical applications, accelerating the development of new treatments.
Her involvement in initiatives such as Stand Up to Cancer demonstrates her dedication to collaborative research and the rapid translation of scientific findings into patient care.
Dr. Perez believes that the future of cancer therapy will involve a combination of approaches, including targeted therapies, immunotherapies, and personalized treatments based on individual patient characteristics.
According to a 2017 report by the American Society of Clinical Oncology, the future of cancer care will be characterized by increased personalization, the use of innovative technologies, and a focus on prevention and early detection.
16. How Does Edith Perez Advocate for Patient-Centered Care?
Edith Perez’s advocacy for patient-centered care is evident in her passion for patient care, her involvement in philanthropic endeavors, and her commitment to health equity.
Her direct involvement in patient care allows her to understand the challenges and needs of cancer patients firsthand.
Her co-development of the 26.2 National Marathon to Finish Breast Cancer demonstrates her commitment to raising funds and providing support for underserved women with breast cancer.
Her role as Chair of the Health Equity Committee for Stand Up to Cancer reflects her dedication to addressing healthcare disparities and ensuring that all patients have access to quality care.
Patient-centered care involves treating patients as individuals, respecting their preferences and values, and involving them in decision-making about their care.
According to the Institute of Medicine, patient-centered care is essential for improving healthcare quality and outcomes.
17. What Ethical Considerations Guide Edith Perez’s Work?
Ethical considerations are paramount in Edith Perez’s work, guiding her approach to research, patient care, and leadership.
Her commitment to ethical & scientific rigor for decision-making ensures that her work is conducted with integrity and transparency.
Her leadership in IDMC (Independent Monitoring Boards) underscores her dedication to protecting the rights and welfare of clinical trial participants.
Her focus on health equity and diversity reflects her commitment to addressing disparities and ensuring that all individuals have access to quality care.
Ethical considerations in medical research include obtaining informed consent from participants, protecting their privacy, minimizing risks, and ensuring that research is conducted with integrity and transparency.
According to the World Medical Association’s Declaration of Helsinki, medical research involving human subjects must be conducted in accordance with ethical principles that protect the rights and welfare of participants.
18. How Does Edith Perez Stay Updated with Scientific Advancements?
Edith Perez stays updated with scientific advancements through her active involvement in research, her participation in scientific conferences and meetings, and her engagement with academic and industry colleagues.
Her role as a professor and researcher allows her to stay at the forefront of scientific discoveries and technological innovations.
Her membership in organizations such as ASCO and AACR provides opportunities to learn about the latest advances in cancer research and treatment.
Her interactions with academic thought leaders, investigators, and industry partners keep her informed about emerging trends and new developments in the field.
Continuous learning and professional development are essential for staying current with scientific advancements in the rapidly evolving field of medicine.
According to a 2010 report by the National Academies of Sciences, Engineering, and Medicine, lifelong learning is critical for healthcare professionals to provide high-quality care in a changing world.
19. How Does Edith Perez Inspire Future Generations of Scientists?
Edith Perez inspires future generations of scientists through her mentorship, her leadership, and her passion for research and patient care.
Her mentorship of young scientists and researchers provides them with guidance and support to pursue their career goals.
Her leadership in academic, industry, and philanthropic organizations demonstrates the impact that scientists can have on society.
Her passion for research and patient care serves as an example for aspiring scientists, motivating them to pursue careers in science and medicine.
Mentorship, role modeling, and inspiration are essential for attracting and retaining talented individuals in the scientific workforce.
According to a 2012 report by the President’s Council of Advisors on Science and Technology, inspiring and preparing the next generation of scientists and engineers is critical for maintaining U.S. competitiveness in the global economy.
20. What Resources Can Pioneer-Technology.Com Provide Regarding Emerging Technologies?
Pioneer-technology.com serves as a comprehensive platform for staying informed about the latest emerging technologies, offering in-depth analysis, expert insights, and up-to-date news.
Our articles cover a wide range of topics, including artificial intelligence, biotechnology, renewable energy, and more.
We provide detailed explanations of complex concepts, making them accessible to a broad audience.
Our expert contributors offer unique perspectives and insights on the potential impact of emerging technologies.
Pioneer-technology.com provides a wealth of resources for anyone interested in learning more about emerging technologies and their potential to transform our world.
A Call to Action for Tech Enthusiasts and Innovators
Ready to dive deeper into the world of pioneering technology? Visit pioneer-technology.com today to explore our latest articles, discover groundbreaking innovations, and stay ahead of the curve in the ever-evolving tech landscape. Don’t miss out on the opportunity to expand your knowledge and connect with a community of like-minded individuals.
For further information or collaboration inquiries, please contact us at:
Address: 450 Serra Mall, Stanford, CA 94305, United States
Phone: +1 (650) 723-2300
Website: pioneer-technology.com
Frequently Asked Questions (FAQ) About Edith Perez and the Puerto Rico Science Technology & Research Trust
1. Who is Edith Perez?
Edith Perez is an internationally recognized translational researcher and cancer specialist, known for her work in oncology drug development and clinical trials.
2. What is the Puerto Rico Science Technology & Research Trust?
The Puerto Rico Science Technology & Research Trust is an organization dedicated to promoting scientific research and technological innovation in Puerto Rico.
3. How is Edith Perez connected to Puerto Rico?
Edith Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan, establishing her connection to the island.
4. What are Edith Perez’s key skills in oncology?
Her skills include medical leadership, translational clinical trials, biomarker research, and precision medicine.
5. What is Edith Perez’s role at Bolt Biotherapeutics?
She is the Chief Medical Officer, responsible for overseeing clinical, regulatory, and medical affairs activities.
6. How did Edith Perez contribute to Genentech/Roche?
She led a diverse medical portfolio and played a key role in the development of cancer immunotherapy.
7. What were Edith Perez’s contributions at Mayo Clinic Cancer Center?
She served as a professor, researcher, and leader, focusing on translational research and clinical trials.
8. What notable clinical trial did Edith Perez lead?
She was the principal investigator of the NCI-funded N9831 trial, which improved outcomes for women with HER2-positive breast cancer.
9. How can the Puerto Rico Science Technology & Research Trust leverage Edith Perez’s expertise?
The Trust can collaborate with her on research projects, invite her as a strategic advisor, and organize workshops to train local scientists.
10. What is the significance of Edith Perez’s work in precision medicine?
Her work in precision medicine focuses on tailoring medical treatment to the individual characteristics of each patient, particularly in oncology.
